Animation Cd Language Language Medicine Medicine Rom

Shares jump after company says that its prostate cancer drug could go to market in 2008.

Super-cheap genetic scanning is set to jolt medicine, offering patients new insights--and painful choices.

In an ever-more stressful business world, today's senior managers must protect their most important asset: their health and well-being.

The embattled biotech's shares slid on Thursday amid concern that the FDA will not approve its prostate cancer drug for years.

Glaxo did its own analysis of Avandia, showing results similar to the one published Monday.